Investigational drug · Phase 2
JCXH-105
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Herpes Zoster (HZ), Infectious Diseases, Shingles.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JCXH-105"
First trial start
2024
Oct 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JCXH-105", any sponsor or status.
Conditions studied
As listed on its trial records.
- Herpes Zoster (HZ)
- Infectious Diseases
- Shingles
Approved drugs for the same conditions: Herpes and shingles · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "JCXH-105" as an intervention, largest first.
- A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster VaccinePivotal-lookingActive, not recruiting
Immorna Biotherapeutics, Inc.Industry
NCT06581575 · 467 participants · Start Oct 16, 2024 · Primary completion Feb 19, 2026
Drug: JCXH-105; Shingrix · For: Herpes Zoster (HZ); Infectious Diseases; Shingles
Sites: Tucson, Arizona; Long Beach, California; Chicago, Illinois · 8 sites in all
Immorna Biotherapeutics, Inc.Industry
NCT05871541 · 75 participants · Start May 26, 2023 · Primary completion Mar 25, 2024
Drug: JCXH-105; Active Control (Shingrix) · For: Herpes Zoster (HZ); Shingles; Infectious Disease
Sites: Hollywood, Florida; Tampa, Florida; Berlin, New Jersey
- Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)Not yet recruiting
Immorna Biotherapeutics, Inc.Industry
NCT07947173 · 72 participants (planned) · Start Nov 2026 · Primary completion Mar 2028
Drug: JCXH-105; Placebo · For: Herpes Zoster (HZ)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Herpes Zoster (HZ)
- CHO Cellrecombinant zoster vaccine, Recombinant Respiratory Syncytial Virus VaccinePhase 39 trials
MAXVAX Biotechnology Limited Liability Company · Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.